Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity.
Reviews in the Neurosciences 1999 DOI: 10.1515/revneuro.1999.10.1.59 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal model study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Phencyclidine (PCP) antipsychotic drug treatment |
| Key points | PCP dose-dependently induces stereotyped behavior and social withdrawal in rats, which may model positive and negative symptoms of schizophrenia; antipsychotic drugs selectively reduce these behaviors. |
Abstract
Phencyclidine (PCP) is a hallucinogenic drug that can mimic several aspects of the schizophrenic symptomatology in healthy volunteers. In a series of studies PCP was administered to rats to determine whether it was possible to develop an animal model of the positive and negative symptoms of schizophrenia. The rats were tested in the social interaction test and it was found that PCP dose-dependently induces stereotyped behaviour and social withdrawal, which may correspond to certain aspects of the positive and negative symptoms, respectively. The effects of PCP could be reduced selectively by antipsychotic drug treatment, whereas drugs lacking antipsychotic effects did not alleviate the PCP-induced behaviours. Together these findings indicate that PCP effects in the rat social interaction test may be a model of the positive and negative symptoms of schizophrenia with face and predictive validity and that it may be useful for the evaluation of novel antipsychotic compounds.
Citations in the library
Cited by 14
- The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats. Frontiers in Psychiatry 2024
- Hallucinogens. Pharmacology & Therapeutics February 1, 2004
- Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice. Psychopharmacology October 1, 2023
- Phencyclidine increased while isolation rearing did not affect progressive ratio responding in rats: Investigating potential models of amotivation in schizophrenia. Behavioural Brain Research May 17, 2019
- Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction. Behavioural Brain Research September 17, 2018
and 9 more in the library
Cites 25
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats Science August 28, 1998
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
and 20 more in the library